Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark

View Full Paper
Ask AI
Bookmark
Share

Authors

EBEugène BrailovskiXWXia WuCWChristopher Wanjiku

Discussion

Loading...

Member takes

Overview

Multicenter retrospective cohort study finds notable hematologic responses to second-line therapies in AL amyloidosis patients after upfront daratumumab treatment.

Key Points

  • Optimal hematologic responses to second-line therapies were observed in 94% of patients treated with venetoclax, indicating its significant effectiveness for AL amyloidosis.
  • Among 195 patients, the presence of t(11;14) cytogenetics was common, leading to different therapeutic responses in AL amyloidosis treatments.
  • Retrospective cohort study assessed second-line therapies in patients who did not respond to upfront daratumumab and bortezomib treatment.
  • Significant variability in responses highlights a need for standardized second-line therapies in AL amyloidosis patients.

Cite This Study

Brailovski et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e03bhttps://doi.org/10.1182/blood-2025-5746
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiac risk factors and cardiac events in patients with newly diagnosed amyloid light chain (AL) amyloidosis from the Phase 2 aquarius study of daratumumab (DARA) plus bortezomib, cyclophosphamide, and dexamethasone (D-VCd)2025 · 1 citations
  2. 2Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy2025
  3. 3Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India2025
  4. 4An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis2025
  5. 5Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy2025